Journal of Biotechnology & Biomaterials
Open Access

Abstract

Viral diseases are still one of the most pressing global problems of society throughout the world. The problem of effectiveness and safety for currently used antiviral therapy is still a major concern; a principally new approaches and the creation on their basis of the original preparations are strongly required. The development of drugs capable of boosting host immune response and affecting target molecules involved in viral pathogenesis seems to be very promising in this respect. Products formulated on the basis of released-active forms of antibodies (RA Abs) meet this needs. The recent years brought persuasive results of RA Abs efficacy obtained in a variety models against a number of viral diseases. For instance, in a models of influenza, rota–, rhino– and herpes viruses the reduction of pathogen titers, resolution of symptoms along with the higher survival rates were demonstrated. For retroviral infection an inhibition of main viral factors involved in the process of penetration and replication was examined. Apart from that, the drugs demonstrated an excellent safety profile in full-scale toxicity studies. Thus, drugs on the base of RA Abs seems to be a worthy candidates for further development and investigation.

Biography

Petrova Natalia Vladimirovna has graduated from Saratov State University named after Chernyshevsky and since that time she launched into the scientific work. She was honoured to take part in international scientific project Marie Curie Actions: International Research Staff Exchange Scheme (Institutte of Transfusion Medicine, Berlin). At the moment, she is involved in her Postdoctoral studies at the Institute of General Pathology and Pathophysiology, where she is currently taking a position of Research Associate. She is a co-author of seven papers in reputed journals.

E-mail: nataliyaapetrova89@gmail.com